Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
PMID: 34871089
2022
Antimicrobial agents and chemotherapy
Result: The most frequent treatment-emergent NRTI RAM was M184V (4/15 patients [26.7%]).
Result: Three patients had both treatment-emergent RPV RAM E138K and NRTI RAM M184V at the last post-baseline time point with genotypic data.
Discussion: The most common treatment-emergent RPV and NRTI RAMs were E138K and M184V, respectively.
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Abstract: M184V mutation was harboured more commonly in the recent PrEP use group (30% vs.
Abstract: DISCUSSION: Rapid PrEP intensification to ART allowed to achieve high rates of HIV viral suppression despite significant rates of M184V mutation harboured in those newly diagnosed with HIV and reporting recent PrEP exposure.
Result: Among those harbouring a Discussion: At least two-thirds of those carrying a M184V/I mutation in our cohort acquired HIV recently, with a large majority reporting sub-optimal PrEP adherence, irrespectively of the PrEP scheme adopted, confirming the trend observed previously in our cohort and in other reports.
Discussion: We confirm high rates of acquired viral resistance to emtricitabine, mostly in the form of M184V/I mutation, harboured in almost a third of these cases.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Result: Notably, 4 had INSTI-R combined with NRTI-R substitutions relevant to the emtricitabine (FTC) or TAF components of the B/F/TAF regimen (M184V and/or K70E).
Table: M184V/I
Table: M184V
Discussion: In the 3 real-world cases, other INSTI-R substitutions were also noted, including L74I, E138K, S147G, and H51Y, along with M184V in RT.
Discussion: The accumulation of multiple INSTI-R mutations, along with M184V, which confe
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
PMID: 35001501
2022
Journal of the International AIDS Society
Abstract: Six (5.9%) participants experienced virologic failure, two of whom had RPV-associated mutations (K101E and Y181C) and a lamivudine-associated mutation (M184V/I).
Discussion: While no emergence of RPV resistance was observed in the 4.1% of study participants with virologic failure in the adult study, two of six adolescents with virologic failure in our study developed RPV RAMs (K101E and Y181C) and a lamivudine-associated mutation (M184V/I).
Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa.
Abstract: Among adult participants, factors associated with preexisting M184 V/I included other resistance, Black race, Hispanic/Latinx ethnicity, lower baseline CD4 cell count, advanced HIV disease, longer duration of antiretroviral therapy, and greater number of prior third agents.
Abstract: At last on-treatment visit, 98% (179/182) with preexisting M184 V/I and 99% (2012/2034) of all B/F/TAF-treated participants had HIV-1 RNA <50 copies/mL, with no treatment-emergent resistance to B/F/TAF.
Abstract: CONCLUSIONS: M184 V/I was detected in 10% of virologically suppressed clinical trial participants at study baseline.
Abstract: Most substitutions were M184 V (n = 161) or M184 V/I mixtures (n = 10).
Abstract: OBJECTIVE: We in
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
Discussion: A combination of RAM similar to those found in this case (M184V, K65R, V108I and E138A) has not been reported in PrEP users.
Discussion: Although theoretically possible, it is unlikely that the short-term and limited drug exposure was sufficient to select for both M184V and K65R, with only few M184V mutations, and even more rarely K65R, described in the literature.
Discussion: However, six cases of HIV infection despite PrEP use have been described previously; in two cases both M184V and K65R were identified.
Discussion: Possible explanations for the PrEP failure in our
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
PMID: 35491829
2022
Antimicrobial agents and chemotherapy
Abstract: Isolate hypersusceptibility to ISL required F227C, in contrast to zidovudine, an NRTI, which required M184V.
Abstract: Six isolates bearing NRTI RAMs (M184V and/or K65R) were resistant to lamivudine (3TC) and emtricitabine (FTC) but not to other approved NRTIs.
HIV mutation literature information.
PMID: 
2022
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT